Publications by Ilhan, H.

2020

Mittlmeier, Lena M.; Unterrainer, Marcus; Rodler, S.; Todica, A.; Albert, Nathalie L. ORCID: 0000-0003-0953-7624; Burgard, C.; Cyran, C. C.; Kunz, W. G.; Ricke, J.; Bartenstein, P.; Stief, C. G.; Ilhan, H.; Staehler, Michael (2020): 18F-PSMA-1007 PET/CT for response assessment in patients with metastatic renal cell carcinoma undergoing tyrosine kinase or checkpoint inhibitor therapy: preliminary results. In: European journal of nuclear medicine and molecular imaging [PDF, 2MB]

Ilhan, H.; la Fougere, C.; Krause, B. J. (2020): PSMA-basierte Theranostik beim Prostatakarzinom. Von der Bildgebung zur Therapie. In: Urologe, Vol. 59, No. 5: pp. 617-623

Unterrainer, M.; Eze, C.; Ilhan, H.; Marschner, S.; Roengvoraphoj, O.; Schmidt-Hegemann, N. S.; Walter, F.; Kunz, W. G.; Munck af Rosenschold, P.; Jeraj, R.; Albert, Nathalie L. ORCID: 0000-0003-0953-7624; Grosu, A. L.; Niyazi, M.; Bartenstein, P.; Belka, C. (2020): Recent advances of PET imaging in clinical radiation oncology. In: Radiation Oncology, Vol. 15, No. 1, 88

2019

Unterrainer, M.; Niyazi, M.; Tonn, J. C.; Ilhan, H.; Bartenstein, P.; Albert, Nathalie L. ORCID: 0000-0003-0953-7624 (2019): A look ahead: future directions of SSR-directed imaging and therapy in meningioma. In: Clinical and Translational Imaging, Vol. 7, No. 5: pp. 357-362

Rudisile, S.; Gosewisch, A.; Wenter, V; Unterrainer, M.; Boening, G.; Gildehaus, F. J.; Fendler, W. P.; Auernhammer, C. J.; Spitzweg, C.; Bartenstein, P.; Todica, A.; Ilhan, H. (2019): Salvage PRRT with Lu-177-DOTA-octreotate in extensively pretreated patients with metastatic neuroendocrine tumor (NET): dosimetry, toxicity, efficacy, and survival. In: BMC Cancer, Vol. 19, No. 1, 788

Unterrainer, M.; Niyazi, M.; Tonn, J. C.; Ilhan, H.; Bartenstein, P.; Albert, Nathalie L. ORCID: 0000-0003-0953-7624 (2019): Current status of SSR-directed imaging and therapy in meningioma. In: Clinical and Translational Imaging, Vol. 7, No. 3: pp. 171-180

2017

Zollner, B. D.; Vettermann, F.; Ilhan, H.; Albert, Nathalie L. ORCID: 0000-0003-0953-7624; Ganswindt, U.; Belka, C.; Niyazi, M. (2017): [68Ga]DOTATATE-PET-basierte Zielvolumendefinition bei Meningeomen WHO Grad I. In: Strahlentherapie und Onkologie, Vol. 193: S152-S152

Paprottka, K. J.; Schoeppe, F.; Ingrisch, M.; Rübenthaler, J.; Sommer, N. N.; Toni, E. de; Ilhan, H.; Zacherl, M.; Todica, A.; Paprottka, P. M. (2017): Pre-therapeutic factors for predicting survival after radioembolization: a single-center experience in 389 patients. In: European Journal of Nuclear Medicine and Molecular Imaging, Vol. 44, No. 7: pp. 1185-1193

Jakobs, T. F.; Paprottka, K. J.; Raeßler, F.; Strobl, F.; Lehner, S.; Ilhan, H.; Trumm, C. G.; Fendler, W. P.; Sommer, W.; Paprottka, P. M. (2017): Robust evidence for long-term survival with Y-90 radioembolization in chemorefractory liver-predominant metastatic colorectal cancer. In: European Radiology, Vol. 27, No. 1: pp. 113-119

Walter, F.; Jell, C.; Ilhan, H.; Belka, C.; Niyazi, M.; Jensen, A. D.; Falk, R. (2017): Anwendbarkeit semiautomatischer PET-Konturierung anhand des biologischen Tumorvolumens zur Zielvolumendefinition beim Ösophaguskarzinom. In: Strahlentherapie und Onkologie, Vol. 193: S174-S175

2016

Delker, A.; Gosewisch, A.; Rieger, S.; Ilhan, H.; Fendler, W.; Gildehaus, F.; Bartenstein, P.; Boening, G. (2016): Dosimetry for Lu-177-PSMA therapy of patients with mCRPC: A comparison of 3D SPECT and 2D planar methods. In: European Journal of Nuclear Medicine and Molecular Imaging, Vol. 43: S213-S214